| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/23/2023 | 227.87% | HC Wainwright & Co. | $9 → $6 | Maintains | Buy |
| 06/15/2023 | 227.87% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 06/12/2023 | 391.8% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 06/09/2023 | 227.87% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 04/13/2023 | 391.8% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
| 02/17/2023 | 391.8% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
| 10/25/2022 | 391.8% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
| 09/27/2022 | 1430.05% | SVB Leerink | $25 → $28 | Maintains | Outperform |
| 09/15/2022 | 227.87% | JMP Securities | → $6 | Initiates Coverage On | → Market Outperform |
| 05/18/2022 | 1266.12% | SVB Leerink | $23 → $25 | Maintains | Outperform |
| 11/16/2021 | 992.9% | SVB Leerink | $24 → $20 | Maintains | Outperform |
| 08/17/2021 | 1211.48% | SVB Leerink | $26 → $24 | Maintains | Outperform |
| 04/19/2021 | 1156.83% | Jefferies | → $23 | Initiates Coverage On | → Buy |
| 04/19/2021 | 1102.19% | JP Morgan | → $22 | Initiates Coverage On | → Overweight |
| 04/19/2021 | 1320.77% | SVB Leerink | → $26 | Initiates Coverage On | → Outperform |
What is the target price for LAVA Therapeutics (LVTX)?
The latest price target for LAVA Therapeutics (NASDAQ: LVTX) was reported by HC Wainwright & Co. on August 23, 2023. The analyst firm set a price target for $6.00 expecting LVTX to rise to within 12 months (a possible 227.87% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for LAVA Therapeutics (LVTX)?
The latest analyst rating for LAVA Therapeutics (NASDAQ: LVTX) was provided by HC Wainwright & Co., and LAVA Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for LAVA Therapeutics (LVTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LAVA Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LAVA Therapeutics was filed on August 23, 2023 so you should expect the next rating to be made available sometime around August 23, 2024.
Is the Analyst Rating LAVA Therapeutics (LVTX) correct?
While ratings are subjective and will change, the latest LAVA Therapeutics (LVTX) rating was a maintained with a price target of $9.00 to $6.00. The current price LAVA Therapeutics (LVTX) is trading at is $1.83, which is out of the analyst's predicted range.